000048453 001__ 48453
000048453 005__ 20200221144118.0
000048453 0247_ $$2doi$$a10.1371/journal.pone.0153028
000048453 0248_ $$2sideral$$a94406
000048453 037__ $$aART-2016-94406
000048453 041__ $$aeng
000048453 100__ $$0(orcid)0000-0001-7866-2803$$aUranga, S$$uUniversidad de Zaragoza
000048453 245__ $$aGranzyme A Is Expressed in Mouse Lungs during Mycobacterium tuberculosis Infection but Does Not Contribute to Protection In Vivo
000048453 260__ $$c2016
000048453 5060_ $$aAccess copy available to the general public$$fUnrestricted
000048453 5203_ $$aGranzyme A, a serine protease expressed in the granules of cytotoxic T and Natural Killer cells, is involved in the generation of pro-inflammatory cytokines by macrophages. Granzyme A has been described to induce in macrophages in vitro the activation of pro-inflammatory pathways that impair intracellular mycobacterial replication. In the present study, we explored the physiological relevance of Granzyme A in the control of pulmonary Mycobacterium tuberculosis infection in vivo. Our results show that, even though Granzyme A is expressed by cytotoxic cells from mouse lungs during pulmonary infection, its deficiency in knockout mice does not have an effect in the control of M. tuberculosis infection. In addition our findings indicate that absence of Granzyme A does not affect the protection conferred by the live-attenuated M. tuberculosis vaccine MTBVAC. Altogether, our findings are in apparent contradiction with previously published in vitro results and suggest that Granzyme A does not have a crucial role in vivo in the protective response to tuberculosis.
000048453 536__ $$9info:eu-repo/grantAgreement/ES/MINECO/SAF2014-54763-C2-1-R$$9info:eu-repo/grantAgreement/ES/MINECO/BIO2014-5258P$$9This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No H2020 643381-TBVAC2020$$9info:eu-repo/grantAgreement/EC/H2020/643381/EU/TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development/TBVAC2020
000048453 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000048453 590__ $$a2.806$$b2016
000048453 591__ $$aMULTIDISCIPLINARY SCIENCES$$b15 / 63 = 0.238$$c2016$$dQ1$$eT1
000048453 592__ $$a1.236$$b2016
000048453 593__ $$aAgricultural and Biological Sciences (miscellaneous)$$c2016$$dQ1
000048453 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000048453 593__ $$aBiochemistry, Genetics and Molecular Biology (miscellaneous)$$c2016$$dQ1
000048453 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000048453 700__ $$0(orcid)0000-0001-8644-120X$$aMarinova, D$$uUniversidad de Zaragoza
000048453 700__ $$0(orcid)0000-0003-2993-5478$$aMartin, C$$uUniversidad de Zaragoza
000048453 700__ $$0(orcid)0000-0003-0154-0730$$aPardo, J$$uUniversidad de Zaragoza
000048453 700__ $$0(orcid)0000-0001-7897-9173$$aAguilo, N$$uUniversidad de Zaragoza
000048453 7102_ $$11008$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Microbiología
000048453 7102_ $$11008$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cÁrea Inmunología
000048453 7102_ $$11008$$2X$$aUniversidad de Zaragoza$$bDpto. Microb.Med.Pr.,Sal.Públ.$$cProy. investigación HQA
000048453 773__ $$g11, 4 (2016), [8 pp]$$pPLoS One$$tPloS one$$x1932-6203
000048453 8564_ $$s529628$$uhttps://zaguan.unizar.es/record/48453/files/texto_completo.pdf$$yVersión publicada
000048453 8564_ $$s104644$$uhttps://zaguan.unizar.es/record/48453/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000048453 909CO $$ooai:zaguan.unizar.es:48453$$particulos$$pdriver
000048453 951__ $$a2020-02-21-13:02:26
000048453 980__ $$aARTICLE